Where is SOLY (+37% from our initial alert) headed next?

by Mike Paulenoff
March 22, 2021 • 11:51 AM EDT
Soliton (SOLY) rallied 37% in the weeks after Mike Paulenoff highlighted it for MPTrader members on March 10. Where's it headed next?
SOLY is a medical device/biotech company developing a promising product, with a 2-year chart setup that caught Mike's attention early in the year, suggesting sooner than later that price would reflect the underlying company fundamentals.
Early on March 10, with the stock at 13.65, Mike wrote: "SOLY continues to exhibit an extremely promising and potentially explosive intermediate-term set up. Let's notice that into last week's weakness, SOLY spiked down right to its up-sloping 50 DMA (now 11.22), which contained the price pressure, and served as the launch pad for a sharp recovery into a near 2-year resistance zone from 14.00 to 15.50. If SOLY either chews its way through the resistance, or is the beneficiary of a forthcoming bullish catalyst, it has potential for a vertical assault to 20-21 and then to 25-26. At this juncture, anyone long SOLY should use the 50 DMA as a stop level."
Mike continued to monitor SOLY closely thereafter, and noting last (on March 15) that the stock had taken out 10 months of resistance at 13.80-15.50, and looked higher.
The following day, SOLY popped to 18.63.
Where's it headed next? SOLY closed at 17.38 on Friday, atop its two year resistance zone, which now serves as support.
Join Mike and our MPTrader members for their laser-focused discussions about promising technical and fundamental set ups in stocks, ETFs, macro indices, cryptocurrencies, and precious metals.
Mike Paulenoff is the author of MPTrader.com, a real-time diary of his technical analysis & trade alerts on
ETFs for precious metals, energy, currencies, and an array of equity indices and sectors, including international
markets, plus key ETF component stocks in sectors like technology, mining, and banking.
Sign up for a Free 7-day Trial!
Every person on the planet is now aware that early on Saturday night, June 21st, 2025, the U.S. military attacked and severely damaged (destroyed?) Iran's nuclear sites and presumably their ability to produce nuclear materials needed to create a WMD.
Last Wednesday afternoon (6/11/25), with META circling 700 after establishing a 4-month new post-April 2025 recovery rally high at 708.87, this is what we discussed about the current technical setup: Just a heads up that my pattern work is warning me that the 52% upmove from the 4/07 low at 467.31 to today's (6/11) high at 708.87 has the right look of a completed, overextended, overbought, unconfirmed rally peak that leaves the price structure vulnerable to a correction of some magnitude.
On May 6, 2025, during the final hour of trading, and before AMD was scheduled to report quarterly Earnings that evening, I posted the following analysis to our MPTrader Discussion Room:AMD reports Earnings after the close... The only conviction I can derive from my pattern work is that the 4/08/25 low at 76.48, which represented a 66% correction from the March 2024 high at 227.30, has the right look of a significant low that completed a major bear phase.
On April 22, 2025, I posted the following analysis about my technical setup work in XBI (SPDR SP Biotech ETF):XBI (SPDR SP Biotech ETF)-- Could it be? Could it be that the near-40% correction from the 11/11/24 multi-year high at 105.47 to the 4/09/25 low at 66.66 fully discounted all the bad news in this sector? From a BIG Picture perspective, my attached Daily Chart shows this month's spike low into the vicinity of the previous major corrective low-zone starting in May 2022.
In the early afternoon on April 11, this was my note to our members:"IBIT (iShares Bitcoin Trust ETF)-- From a trading perspective, anyone who is in sync with the Bitcoin setup might consider owning IBIT (iShares Bitcoin ETF) against a stop below its 4/07/25 low at 42.98 (see my attached Daily Chart below)...